ArticleCVIR endovascular2026
Endovascular flow reduction after portal vein arterialization: a technical note.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePortal vein arterialization (PVA) is a salvage technique used to preserve hepatic and biliary perfusion when hepatic arterial reconstruction is not feasible. Excessive arterioportal inflow, however, may cause clinically relevant portal hyperperfusion with ascites, gastrointestinal or biliary bleeding, and hepatic dysfunction. This technical note describes a practical interventional radiology approach to temporary, graded, and definitive endovascular flow modulation after PVA. MATERIALS AND
methodsAll consecutive patients with native livers who underwent PVA at a tertiary referral center between February 2020 and February 2024 were retrospectively reviewed. Cases requiring endovascular flow reduction for portal hyperperfusion were analyzed with regard to indication, timing, technique selection, technical feasibility, and short-term clinical course. Technical success was defined as correct device deployment with immediate angiographic reduction of arterioportal inflow. Procedure-related complications were classified according to CIRSE.
resultsSix patients required endovascular flow modulation after PVA, accounting for nine procedures. Balloon occlusion with repositioning was used as a temporary measure and a hemodynamic test when definitive closure was considered premature. Stent-based flow modulation was used for graded reduction when persistent hyperperfusion required decompression but residual shunt perfusion was to be preserved. Coil embolization was used for definitive closure in refractory cases or when complete occlusion was deemed acceptable. Technical success was achieved in 7/9 procedures and clinical success in 5/9. Despite technically successful flow reduction, two patients died from septic multiorgan failure.
conclusionEndovascular flow modulation after PVA is technically feasible using complementary IR strategies. Balloon occlusion is useful for temporary or test reduction, stent techniques for partial flow modulation, and coil embolization for definitive closure. Technique selection should be guided by timing after PVA, clinical presentation, and anticipated hepatic tolerance rather than by a uniform treatment algorithm.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.